Veeva Basics Adopted by More Than 100 Emerging Biotechs to Simplify and Standardize Operations

Rhea-AI Summary

Veeva Systems (NYSE: VEEV) announced on November 4, 2025 that more than 100 biotechs across 60 companies have adopted Veeva Basics to standardize clinical, regulatory, and quality operations. Veeva Basics uses pre-configured, pre-validated applications on the Vault Platform for fast deployment and seamless upgrade to full Vault solutions.

Two new applications—Veeva LIMS Basics and Veeva PromoMats Basics—are planned for availability in early 2026, with stability functionality for LIMS planned for 2026. More information at veevabasics.com.

Positive

• >100 biotechs adopted Veeva Basics
• 60 companies represented among adopters
• Pre-configured, pre-validated apps enable fast deployment
• Built on Vault Platform for seamless scale to full solutions
• Veeva LIMS Basics and PromoMats Basics planned early 2026

Negative

• Stability functionality for LIMS not available until 2026

Insights

Commercial SaaS and Life Sciences GTM Strategist

Veeva Basics shows measurable early commercial traction with 100+ biotech adopters and product expansion toward QC and promotional needs.

Veeva Basics now counts more than 100 biotech adopters across 60 companies as of Nov. 4, 2025, and the product line will add Veeva LIMS Basics and PromoMats Basics for availability in early 2026. The offering is positioned as pre-configured and pre-validated applications on the Vault Platform, enabling customers to adopt core clinical, regulatory, and quality workflows quickly without migration.

Adoption at this scale signals early market fit for a standardized, low-friction entry product. Execution risks include timely delivery of the announced LIMS and PromoMats functionality and the planned stability features in 2026. The announcement lists customer endorsements that highlight standardization, compliance, and faster onboarding as tangible customer benefits.

Watch for two concrete milestones: availability of LIMS and PromoMats in early 2026 and the rollout of stability functionality planned for 2026. These items provide short-term signals of product execution and scaling capacity over the next 6–12 months.

New applications include Veeva LIMS Basics and PromoMats Basics to drive speed and growth

PLEASANTON, Calif., Nov. 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 100 biotechs have selected Veeva Basics to advance operations across clinical, regulatory, and quality. A growing number of biotechs in the U.S. and Europe are establishing a foundation for growth with a simple and standard industry-leading solution that can scale as business needs evolve.

With Veeva Basics, biotechs leverage best-of-breed industry applications that are pre-configured and pre-validated for fast deployment. Veeva Basics is built on the Vault Platform, enabling biotechs to move to a full Vault solution with no migration required. This provides companies with the technology and support for efficient processes across key business areas now and for the long term.

"More than 100 biotech leaders across 60 companies came together at Veeva R&D and Quality Summit in Boston to learn, connect, and shape the future of Veeva Basics. We're proud of the impact Veeva Basics is making on emerging biotechs and will continue to add innovative new applications that can be implemented quickly to support the development of new medicines," said Steve Harper, general manager of Veeva Basics.

To meet critical quality control (QC) and commercial needs, Veeva Basics is adding two new applications:

• Veeva LIMS Basics for virtual companies to enable CMO oversight, including batch release and certificate of analysis (CoA) capabilities. Stability functionality planned for 2026.
  
  
• Veeva PromoMats Basics for full content lifecycle management, including approval, storage, and distribution of promotional content and claims management.

Veeva LIMS (laboratory information management) Basics and PromoMats Basics are planned for availability in early 2026. Built on the proven Vault Platform, Veeva Basics applications help customers to scale their technology infrastructure as they grow. For more on Veeva Basics, visit veevabasics.com.

What biotechs are saying about Veeva Basics:

"As a fast-growing company, we understood the value of Veeva Basics standardizing our processes based on industry best practice. Knowing we have an agile solution that works now, while providing easy access to the Veeva Vault Platform as we grow, gives us peace of mind that we can meet future requirements," said Richard Tornai, senior director IT, R&D Clinical at Structure Therapeutics.

"Building a foundation for our quality and regulatory operations was a priority and we needed a compliant, cost-effective solution for document and record management. We believe Veeva Basics fits those needs and more by providing logical workflows, a templated library of SOPs and forms, and simple and effective training," said Bryan Ball, chief technical operations officer at Whitehawk Therapeutics.

"Veeva Basics delivered a best-of-breed solution with the global support to upskill our staff quickly. Veeva's commitment to delivering innovation for biotechs and its focus on customer success make it the ideal partner," said Bernhard Irlinger, head of quality at AiCuris.

About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/veeva-basics-adopted-by-more-than-100-emerging-biotechs-to-simplify-and-standardize-operations-302603762.html

SOURCE Veeva Systems

FAQ

How many biotechs have adopted Veeva Basics as of November 4, 2025 (VEEV)?

More than 100 biotechs across 60 companies have selected Veeva Basics.

What new Veeva Basics applications are planned in early 2026 for VEEV?

Veeva LIMS Basics and Veeva PromoMats Basics are planned for availability in early 2026.

When will stability functionality for Veeva LIMS Basics be available for VEEV customers?

Stability functionality is planned for availability in 2026.

Can Veeva Basics customers move to full Vault solutions without data migration (VEEV)?

Yes; Veeva Basics is built on the Vault Platform and allows move to a full Vault solution with no migration required.

What key areas does Veeva Basics target for emerging biotechs (VEEV)?

Veeva Basics targets clinical, regulatory, and quality operations with compliant document and record management.

Where can investors and customers learn more about Veeva Basics (VEEV)?

More information is available at veevabasics.com.